Evaluation of Renal Damage After PCNL and ESWL Using Novel RNA Based Biomarkers

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05077007

Enrollment

Registered

2021-10-13

Start date

2021-01-01

Completion date

2022-11-01

Last updated

2022-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury, Renal Calculi, Percutaneous Nephrolithotomy, Extracorporeal Shockwave Lithotripsy

Keywords

lncRNA, mRNA, ESWL,PCNL,SBF2-AS1, FENDRR-19, NLRP3.

Brief summary

The study evaluate the damage effect of ESWL and PCNL on kidney tissue by measuring non-coding lnc-RNA profile in urine before and after ESWL and PCNL procedures

Detailed description

The study evaluate the damage effect of ESWL and PCNL on kidney tissue by measuring non-coding lnc-RNA profile in urine before and after ESWL and PCNL procedures and assess their usefulness as diagnostic biomarkers for AKI and the relationship between the selected RNA based biomarker panel and clinicopathological changes of patients.

Interventions

PROCEDUREPercutaneous nephrolithotomy

Endoscopic stone Extraction from the kidney by making a puncture and dilate a tract direct into the kidney through muscle wall and renal parenchyma

PROCEDUREExtracorporeal Shock Wave Lithotripsy

Using Shock waves from outside the body targeted at a kidney stone causing the stone to fragment. The stones are broken into tiny pieces.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Inclusion criteria for patients : 1. Patients undergoing treatment for a stone(s) located in the kidney less than 2 cm 2. Radiopaque stone 3. Able and willing to give informed consent Inclusion criteria for Healthy volunteers 1. No history of kidney or stone disease 2. Asymptomatic 3. No indwelling ureteral stent 4. Willing to provide medical history information 5. Able and willing to give informed consent

Exclusion criteria

Design outcomes

Primary

Measure	Time frame	Description
Evaluation of renal damage after PCNL and ESWL using novel RNA based Biomarkers	Before the procedure by 2hours and after the procedure by 2 and 24 hours	Evaluation of kidney injury after procedures PCNL and ESWL by measuring the change of the level of novel non-coding lnc-RNA profile in urine

Countries

Egypt

Contacts

Primary Contactwaleed Mousa, MD

waleedmousa2@yahoo.com+201067628771

Backup ContactAhmed Tawfick, MD

murmer_urology26@hotmail.com+201223112243

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026